Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, outlines the updated biomarker analysis results of the ASCENT trial (NCT02574455), a Phase III study evaluating the efficacy of sacituzumab govitecan, a novel antibody-drug conjugate against physicians choice chemotherapy in patients with metastatic, triple-negative breast cancer. Trop-2 and BRCA expression was evaluated in these patients to determine whether these markers correlated with the efficacy of the antibody-drug conjugate. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
